Rasonque EMA Recommendation: Promising Survival Gains
Rasonque EMA recommendation: the CHMP backs the oral RAS inhibitor for pretreated metastatic pancreatic cancer. Survival data, side effects, next steps.
Rasonque EMA recommendation: the CHMP backs the oral RAS inhibitor for pretreated metastatic pancreatic cancer. Survival data, side effects, next steps.